Antagonistic Hallmarks at the Bedside — What That Longevity Panel Actually Means

So a 54-year-old hands me a printed longevity panel — fasting glucose 94, HbA1c 5.4%, three things flagged in red: GDF-15 elevated, hs-CRP at 2.8, and something called an epigenetic pace-of-aging score of 1.09. Bottom of the page: rapamycin, senolytics, NMN, question marks. Where do I even start?

Start with what these three flags actually represent. They map onto what the hallmark framework calls the antagonistic tier — nutrient sensing, mitochondrial function, and cellular senescence. Antagonistic means each process was originally protective and becomes harmful only when it persists.

GDF-15 — I know it as a stress marker in heart failure. What's it doing on an aging panel?

GDF-15 is a cytokine released under mitochondrial and metabolic stress. Elevated levels correlate with biological aging in epidemiological data, and it tracks independently from conventional cardiometabolic markers. Useful signal, not yet an actionable treatment target. Observational evidence only.

And the epigenetic pace score — that's a clock based on DNA methylation, the chemical tags on DNA that change predictably with age?

Exactly. A score of 1.09 means the algorithm estimates this person is aging roughly nine percent faster than their chronological peers. DunedinPACE is the most validated of these. It predicts mortality and functional decline in longitudinal cohorts — but no intervention trial has used it as a primary endpoint, so we don't know what moving it means clinically.

So I tell the patient it's a risk signal, not a diagnosis, and there's no proven way to change it?

Correct. Now the interventions. mTOR inhibition — rapamycin targets mTOR, the central nutrient-sensing kinase — extends lifespan robustly in mice. In humans, the PEARL trial showed improved immune responses in older adults at low intermittent doses. No mortality data, no approved longevity indication. I wouldn't prescribe it off-label for this.

Metformin has decades of safety data. Does that change the calculus?

It's in a better position epidemiologically — diabetic cohorts on metformin show lower all-cause mortality than matched non-diabetic controls, which is provocative. The TAME trial is testing it prospectively in non-diabetic older adults with composite aging endpoints. Results aren't in. For a patient with fasting glucose of 94 and HbA1c 5.4%, metformin for longevity remains off-label and unproven.

What about NMN — I assume that's an NAD precursor, where NAD is a cofactor mitochondria need for energy metabolism?

Right. NMN and NR both raise blood NAD levels in humans — that's pharmacokinetic data. Whether raising NAD improves clinical outcomes in aging humans: no trial has shown that yet. Mechanistic and animal data only. Marketed aggressively without clinical endpoint evidence.

Senolytics — drugs that clear senescent cells, meaning cells that have permanently stopped dividing and are secreting inflammatory signals?

The dasatinib-plus-quercetin combination reduced senescent cell burden in small human trials — Mayo and Unity Biotechnology data — with improvements in some physical function measures. Compelling mechanistic rationale, early-phase human data only. Not ready for routine use, and dasatinib carries real toxicity.

So what do I actually do differently in this visit?

Validate the patient's seriousness, then redirect. The hs-CRP at 2.8 is actionable today — lifestyle, statin if indicated by their ASCVD risk. The prediabetes trajectory is real and reversible with exercise and diet, which also moves the mitochondrial and senescence biology as well as anything on that supplement list, with actual human outcome data.

And the one thing to hold onto?

These three hallmarks began as protective responses. The intervention logic follows from that — you're not trying to abolish nutrient sensing or senescence, you're trying to restore appropriate cycling. Nothing on that supplement page does that with proven human endpoint data yet. The exercise prescription does.